Klage gegen Zyprexa off-label Marketing
Der Bundesstaat Montana hat ein Verfahren gegen Lilly wegen der off-label Vermarktung von Zyprexa® eingeleitet.
Lilly allegedly gave kickbacks to doctors and improperly promoted the drug to nursing homes as a sedative, Montana Attorney General Mike McGrath said in a complaint filed March 7 in state court in Helena. He claimed Lilly, the world's biggest maker of psychiatric drugs, bought off a "disgruntled'' sales director to keep him from disclosing its marketing practices.
Lilly created a 280-person sales force "to promote Zyprexa exclusively for off-label uses, specifically for long term care facilities to maximize off-label use of Zyprexa sales" for the elderly, Montana said in its complaint.
Lilly created a 280-person sales force "to promote Zyprexa exclusively for off-label uses, specifically for long term care facilities to maximize off-label use of Zyprexa sales" for the elderly, Montana said in its complaint.
[Zyprexa]
| Autor: strappato 2007-03-13 Link (2 Kommentare) Ihr Kommentar |
hockeystick 2007-03-13
>> Kommentieren
hockeystick 2007-03-15
[...] Big Pharma pays for thousands of speeches by doctors each year because companies can not legally promote off-label uses. So in other words, the law allows drug makers to hire doctors to do the dirty work that would be illegal for the company itself. In 2004, doctors spoke at 237,000 meetings sponsored by drug companies, up from 66,000 in 1999, according to the July 15, 2005, Wall Street Journal. (Quelle)
>> Kommentieren
